Clindamycin concentrations in gingival crevicular fluid and in blood were determined over a 7-h period and were related to the minimal inhibitory concentrations of this agent for 340 bacterial strains isolated from diseased periodontal sites. The clindamycin levels after administration of single 300-mg oral doses were measured in gingival crevicular fluids by using an agar diffusion bioassay. Minimal inhibitory concentrations were determined by agar dilution techniques for 30 species of periodontal bacteria. With the exception of Eikenella corrodens and Actinobacillus actinomycetemcomitans, most of the bacteria were inhibited by a concentration of 1.0 lsg of clindamycin per ml or less. The peak concentrations in crevicular fluid (2.0 ± 0.3 lig/ml) and in blood (1.9 ± 0.3 ,ug/ml) were approximately the same. However, crevicular fluid levels of 1.0 ug/nml and above were present for up to 6 h, whereas blood concentrations dropped below 1.0 ,tg/ml within 2 h after administration. Based on its minimal inhibitory concentrations, clindamycin at crevicular fluid levels of 1.0 ,ug/ml or above should inhibit most bacteria associated with diseased periodontal sites.
The recognition that destructive periodontal diseases are probably caused by specific bacteria has heightened interest in the use of antimicrobial agents as adjuncts in periodontal therapy. Tetracycline has been the most frequently used antibiotic for treatment of periodontal disease in the United States. Data from antibiotic susceptibility testing (15; C. B. Walker, J. M. Gordon, S. J. McQuilkin, T. A. Niebloom, and S. S. Socransky, J. Periodontol., in press) and pharmacokinetic studies (4; J. M. Gordon, C. B. Walker, J. C. Murphy, J. M. Goodson, and S. S. Socransky, J. Clin. Periodontol., in press) have shown that tetracycline is delivered in sufficient quantities to inhibit most organisms at the site of infection, which in periodontal diseases is the pocket or space between the teeth and the gingiva. However, resistance to this drug is not uncommon (15, 18) and may account for patients who continue to lose alveolar bone despite conventional therapy and the adjunctive use of tetracycline. In some patients, susceptibility data have indicated that penicillin may be as effective as tetracycline (7, 15) . However, little is known regarding the penetration of penicillin into the gingival crevicular fluid and its possible degradation by extracellular beta-lactamases. There is currently little information concerning the efficacy of other antibiotics in periodontal therapy. Previous studies have indicated that clindamycin is an effective agent against anaerobic bacterial infections in other parts of the body (6, 12, 13) (17) .
Broth cultures. Broth inocula were prepared by transferring three to five colonies from Trypticase soy broth agar to a broth medium. Fusobacterium, Capnocytophaga, Streptococcus, Selenomonas, and Peptostreptococcus strains were inoculated into MMB. Actinobacillus actinomycetemcomitans was inoculated into MMB to which filter-sterilized NaHCO3 was added at the time of inoculation to give a final concentration of 1 mg/ml. B. gingivalis, B. melaninogenicus, and Bacteroides oralis were inoculated into MMB supplemented with 0.5 ,ug of menadione per ml. Wolinella recta (anaerobic Vibrio), Campylobacter concisus (oral Campylobacter), and Bacteroides gracilis ("corroding" Bacteroides) (S. J. Badger and A. C. R. Tanner, submitted for publication) were inoculated into MMB supplemented with 0.1% sodium formate and 0.15% sodium fumarate. Eikenella corrodens was inoculated into MMB supplemented with 0.1% KNO3. CS4 broth was used for Actinomyces, Propionibacterium acnes, and Lactobacillus strains. All broth cultures were inoculated by using a VPI anaerobic culture system (Bellco Glass, Inc., Vineland, N.J.) and an O2-free gas mixture containing 80% N2, 10% H2, and 10% CO2. Cultures were incubated at 35°C for 24 to 48 h.
MICs. The MICs of clindamycin were determined by using clindamycin hydrochloride susceptibility powder (The Upjohn Co., Kalamazoo, Mich.) and an agar dilution technique, as previously described (16) . The MIC was defined as the lowest concentration of antibiotic that gave no growth.
Agar diffusion assay method. The assay used was a modification of the assay described by Sabath and Toftegaard (8). The modifications described below were necessary to increase the sensitivity of the assay approximately 50-fold, since less than 0.5 pl of crevicular fluid could be collected readily from each gingival crevice site.
The assay organism, Clostridium perfringens ATCC 13124, was maintained by weekly transfers in Todd-Hewitt broth. A seed culture was prepared by transferring 0.8 ml of the stock culture to 9.0 ml of Todd-Hewitt broth and incubating this preparation anaerobically overnight; 0.4 ml of the overnight culture was added to 9.0 ml of Todd-Hewitt broth, and the resulting culture was incubated anaerobically for approximately 2.5 h and then adjusted to an optical density at 550 nm of 0.15.
The assay medium was prepared by adding 0.5 g of agar (Ionagar; Colab Laboratories, Glenwood, Ill.) to 100 ml of brain heart infusion broth (BBL). The brain heart infusion agar medium was adjusted to pH 8.0, autoclaved, and cooled to 46°C. Then, 8 ml of defibrinated whole sheep blood (BBL) and 2.0 ml of the standardized seed culture were added to the medium and 17-ml volumes were poured into large petri plates (150 by 15 mm; VanLab, Boston, Mass.) and allowed to solidify.
Sample strips of gingival fluid and two series of standards were placed onto the assay plates, and the plates were incubated anaerobically at 35°C for 4 to 5 h. Because the zones of inhibition of hemolysis were often elliptical, diameters were measured along both the long axes and the short axes to the nearest 0.1 mm, and the averages were recorded. Blood samples were assayed by the same procedure, except that standards were prepared in defibrinated sheep blood (BBL). Preliminary trials demonstrated that sheep blood was a suitable substitute for pooled human blood and yielded approximately equivalent inhibition zone diameters.
Preparation of standards. A stock solution (1.0 mg/ml) was prepared by dissolving clindamycin hydrochloride in distilled water. Lower concentrations (0.125 through 4.0,ug/ml) were made by dilution with phosphate-buffered 7.0% bovine serum albumin, as previously described (4); 0.5-pl amounts of standard solutions were placed onto filter paper strips (Periopaper; Harco Electronics, Winnipeg, Ontario, Canada) with a 1.0-pl syringe. Standard strips could be stored at -20°C for up to 6 weeks without loss of activity.
Standard curves. Standard curves were fitted by linear regression, using the method of Colquhoun (1) . Since the volumes of the gingival fluid samples varied, zone diameters were converted to absolute amounts of clindamycin per strip, and the concentration in each gingival fluid sample was calculated.
Human subjects. Three volunteers were given single oral 300-mg doses of clindamycin hydrochloride (Cleocin; The Upjohn Co). Gingival fluids and blood were sampled at 30-min intervals for the first 2 h and then at 1-h intervals for an additional 5 h. Blood was collected by finger puncture. Gingival crevicular fluid was collected from four sites in each subject, and the volume from each site was determined by using a gingival fluid meter (Harco Electronics), as previously described (4). All volunteers had minimal or no clinically evident inflammation and had not received antibiotic therapy for at least 3 months before the study. Figure 2 shows the mean crevicular fluid levels and the mean blood levels for the three subjects. Clindamycin reached maximum concentrations in the blood (1.9 ± 0.3 ,ug/ml) in approximately 30 min and in the crevicular fluids (2.0 ± 0.3 ,ug/ ml) in about 90 min after administration. Although the peak concentration in the crevicular fluid was approximately the same as the peak blood level in each volunteer, clindamycin persisted at higher levels in the crevicular fluids than in the blood. Crevicular fluid levels were more than 1 ug/ml for 6 h after the single oral dose and were significantly higher (P < 0.001) than blood levels after the second hour. DISCUSSION Because ofthe small volume of crevicular fluid that can be collected conveniently from a gingival site at one time, it was necessary to optimize the sensitivity of an agar diffusion assay (8) in order to measure clindamycin concentrations in crevicular fluids. The most important parameters that influenced the sensitivity of the assay were (i) the composition of the agar medium, (ii) the turbidity of the assay inoculum, and (iii) the depth of the assay medium. This assay was as sensitive and as reproducible as a similar assay previously described for the quantitation of tetracycline in crevicular fluids (4) .
RESULTS

MICs
Clindamycin reached approximately the same peak concentrations in crevicular fluid and blood, although the peak concentration in crevicular fluid occurred about 1 h later than the peak concentration in blood. However, after the peak concentration was reached, clindamycin remained at higher concentrations in crevicular fluid than in blood, which indicated that higher (Walker, unpublished data) . These strains were included in this study and were inhibited by <1.0 yg of clindamycin per ml.
In conclusion, representative strains of most of the bacteria which have been cultivated from periodontal pockets were inhibited in vitro by clindamycin concentrations that were achieved in crevicular fluid. We believe that it may be possible to use clindamycin as an adjunct to conventional periodontal therapy when tetracycline and penicillin are contraindicated. However, in view of the intestinal disorders associated with clindamycin usage, clinical trials are needed to evaluate fully the risk-to-benefit potential of this drug in periodontal therapy.
